// App-Quantinova.ai

153 : S-1 in combination with docetaxel and oxaliplatin (DOS) every 2 weeks (DOS2w) or every 3 weeks (DOS3w) in patients with advanced gastro-esophageal adenocarcinoma (aGEA): Final results of 2 parallel phase I studies.

Researchers

Presenter

  • Camilla Qvortrup

Principal Investigators

  • Jon Kroll Bjerregaard

  • Per Pfeiffer

Medical Centers

  • Department of Oncology, Odense University Hospital, Odense, Denmark

Locations

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Esophageal Cancer

  • Neutropenia

Biomarkers

  • N/A

Drug/Treatment

  • Oxaliplatin

  • Docetaxel

Outcome

  • N/A

Study Design

  • Fixed Dose

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved